The compression of the median nerve during its passage through the carpal tunnel results in Carpal Tunnel Syndrome (CTS). It is the high pressure inside the carpal tunnel that is the main cause of CTS.
According to NIH, in the general population, CTS affects 1% to 5% of people. With a 3:1 female-to-male ratio, CTS is more common in females than in males. Obese people have a twofold increased chance of acquiring CTS. CTS usually appears in adults between the ages of 40 and 60, and it is rare in teenagers.
The transverse carpal ligament at its top boundary and the carpal bones at its lower limit form the carpal tunnel, a narrow corridor in the wrist. Nine flexor tendons are housed in the carpal tunnel, which also houses the median nerve. The development of CTS is a result of ischemia damage to the median nerve, high blood pressure, and mechanical stress.
Within the carpal tunnel, the typical pressure ranges from 2 to 10 mmHg. But when the wrist is extended or flexed, the pressure rises eight to ten times higher than usual. Repeated compression of a nerve cause demyelination at the point of compression. A disturbance in blood flow to the endoneurial capillary system results in the development of endoneurial edema.
Patients are more susceptible to carpal tunnel syndrome (CTS) due to a number of factors, yet the precise cause of the ailment is still unknown. Changes in the body's fluid balance, modifications to the carpal tunnel, or the presence of direct neuropathic causes increase the likelihood of developing CTS.
Among the risk factors include carpal subluxation or dislocation. Menopause, obesity, kidney failure, pregnancy, hyperthyroidism, oral contraceptive use, diabetes, congestive heart failure, vitamin poisoning or insufficiency, etc.
Symptoms
Carpal tunnel syndrome typically manifests its symptoms gradually and without a specific injury. For a long time, many individuals experience intermittent symptoms. Nevertheless, symptoms become more frequent or last longer as the illness worsens.
The following are symptoms of carpal tunnel syndrome:
Physical Examination
A physical examination is performed by the provider. A physician examines the patient's strength of hand muscles and sensation in their fingers.
Many patients get symptoms when they bend their wrist, tap on the nerve, or just press on the nerve.
Electrophysiological tests
To assess whether the median nerve is under excessive pressure and to examine how effectively the nerve is functioning, doctors prescribe electrophysiological testing of the nerves.
Carpal tunnel syndrome severity and whether the nerve is squeezed in other places is able to be assessed with these tests.
ECG examinations include-
Imaging Test
Diagnostic Market Players |
Diagnostic Product |
General Electric Company (GE Healthcare) |
SIGNA™ MRI |
TECHNOMAC |
SIGNA™ Pioneer |
Siemens Healthineers |
SIGNA™ Architect |
Med Imaging Solutions |
Discovery™ MI |
Canon Medical Systems Corporation |
VUE Point™ FX |
Gastro diagnostic.Ltd |
Ruggles® |
Radiance Imaging system |
Redmond™ |
Fujifilm Holdings Corporation (FUJIFILM Medical Systems) |
SmartRelease® ECTR, LLC., |
Smith & Nephew plc. |
CX50 POC |
CONMED Corporation |
EPIQ Elite |
Integra LifeSciences |
MYOQUICK® |
microaire surgical instruments |
NEUROWERK® |
Stryker Corporation |
|
Sonex Health, LLC |
|
Micromed Solutions for Neurophysiology |
|
The severity of the condition determines the CTS avenues for treatment. Wrist splinting, medicine, and surgery are available forms of treatment. If the patient's symptoms were mild to severe and had been coming and going for less than ten months, splinting and other conservative measures were more likely to be beneficial.
Non-Surgical Intervention
Surgery
Through the cutting of the ligament pushing on the median nerve, carpal tunnel surgery aims to relieve pressure.
Two alternative procedures could be used to execute the surgery.
Medication
Treatment Market Players |
Treatment Products |
GlaxoSmithKline plc |
Gralise® |
Arthrex, Inc |
Horizant® |
Johnson & Johnson Services |
Neurontin® |
Bayer AG |
Gabarone® |
F. Hoffmann-La Roche Ltd |
Aristocort® |
Allergan |
Aleve® |
Pfizer Inc |
Anaprox® |
Mylan N. V |
Naprelan® |
Bristol-Myers Squibb Company |
Naprosyn® |
Eisai Co., Ltd |
BRACEOWL |
Zydus Cadila |
REVIO |
Teva Pharmaceutical Industries Ltd |
ComfyBrace |
Aurobindo Pharma |
ENDOPOUCH RETRIEVER® |
Dr. Reddy’s Laboratories Ltd |
|
Fresenius Kabi AG |
|
Hikma Pharmaceuticals PLC |
|
Novartis AG |
|
WOCKHARDT |
|
Pressure Profile Systems |
|
Endo Pharmaceuticals Inc |
|
PAVmed Inc |
|
Avadim Health, Inc |
|
The most frequently used techniques are open carpal tunnel releasing systems. These techniques are commonly used because they allow for accurate flexor retinaculum vision, direct visualization, and the identification of anatomical abnormalities. CTS is the most common compressive neuropathy, with a reported frequency of 3.8% in the general population, according to an NCBI paper published in June 2022. The benefits of single- or double-portal procedures are combined in mini-open carpal tunnel release (MCTR), which has been shown to have minimal rates of complications. In order to prevent these post-operative issues, open carpal tunnel release is the ideal method, which helps the segment under study expand.
A 2021 survey by the American Association for Hand Surgery revealed that 34% of participants preferred an endoscopic method, 46% preferred a mini-open incision, and 34% selected a regular open (extensile) incision. The expansion of this section of the market is thus anticipated to be driven by patients' desire for open carpal tunnel releasing methods. According to a June 2022 NCBI article, this procedure entails a risk of postoperative wound pain, scar sensibility, and pillar pain, despite its ability to provide direct vision, consistent flexor retinaculum separation, and the measurement of anatomical differences. Open carpal tunnel release (OCTR) is the most commonly used method, and this trend is predicted to increase demand for open carpal tunnel release system procedures.
As a result, elements including the increasing use of open carpal tunnel release devices and their effectiveness are anticipated to propel the segment's expansion throughout the projection period.
The DiseaseLandscape Insights consultancy firm provides valuable support in future market trends on the development of new pharmaceutical products. This support helps to streamline the planning and execution of clinical trials of novel medications and treatments, implement effective patient recruitment strategies, ensure regulatory compliance, and increase the likelihood of successful trial outcomes.
The below table gives information about some currently ongoing clinical trials, including their study titles and respective stages:
Phase 1 |
Phase 2 |
Phase 3 |
Phase 4 |
Radiofrequency, Perineural Injection, Idiopathic Carpal Tunnel Syndrome |
A Study of Fisetin to Treat Carpal Tunnel Syndrome |
Ultrasound-guided Dextrose Injection Versus Dextrose with Methylprednisolone in Carpal Tunnel Syndrome |
A Norwegian Trial Comparing Treatment Strategies for Carpal Tunnel Syndrome |
Conditioning Electrical Stimulation to Improve Outcomes in Carpal Tunnel Syndrome |
Botulinum Toxin Type A for Peripheral Neuropathic Pain in subjects With Carpal Tunnel Syndrome |
The Stoical Study - The Soft Tissue Injection of Corticosteroid and Local Anesthetic Study |
Local Injection of Steroid VS. Glucose 5% in Carpal Tunnel Syndrome |
|
Conditioning Electrical Stimulation to Improve Outcomes in Carpal Tunnel Syndrome |
|
Exparel and Education to Avoid Opioids After Carpal Tunnel Release |
DiseaseLandscape Insights (DLI), a healthcare consulting firm, is prepared to provide a comprehensive range of strategic services to all our stakeholders in order to assist healthcare organizations in managing Carpal Tunnel Syndrome. Numerous services are offered, such as market research and analysis to spot trends and possibilities.
In addition, DLI offers guidance to clients in order to maintain regulatory compliance in a number of areas, including creating innovative product development strategies, collaborating with significant stakeholders, and applying clinical expertise for evidence-based approaches.
By offering personalized advice, DLI services enable clients to make informed decisions that enhance patient outcomes by guiding them through the complicated world of CTS management.
DLI's services make it easier for industry participants to conduct clinical studies for new drugs and treatments. It also facilitates other tasks like patient recruiting and regulatory compliance. DLI also gives industry participants comprehensive information about global regulations and guidelines, market trends, and rivals in the industry.
How we can help?